Tetra Bio-Pharma (OTC: TBPMF) Announces Granting of U.S. Patent for Treatment of Interstitial Cystitis
Tetra strengthens its intellectual property portfolio Approximately 12% of women may have early symptoms of Interstitial Cystitis OTTAWA, ON / April 15, 2021 / Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX:TBP)(OTCQB:TBPMF)(FRA:JAM1), a biopharmaceutical pioneer in immunomodulator […]